Would you add dostarlimab to adjuvant carboplatin/paclitaxel in a patient with completely resected IIIA uterine carcinosarcoma (MSI-H)?  

In the RUBY trial, eligible patients had advanced or recurrent disease not amenable to resection (except stage IIIC, where residual disease was not required). Meanwhile, NCCN guidelines do not discriminate based off sub-categories of advanced stage and FDA approval is also for advanced/recurrent disease. Are you using more strict or more liberal criteria to decide which patients get adjuvant immunotherapy?